The fact sheet for Johnson & Johnson’s Covid-19 vaccine has been revised by U.S. regulators to warn of the risk of a rare bleeding disorder.
The Food and Drug Administration said in a letter to the company on Tuesday that adverse-event reports suggested an increased risk of immune thrombocytopenia, or ITP, during the 42 days following vaccination. Symptoms include bruising or excessive or unusual bleeding, according to the agency.
